In this issue:
Efficacy of risankizumab across subgroups in PsA
PROs and PRO remission rates in PsA patients
Effect of secukinumab and TNFi on humoral response to mRNA vaccine patients
Prevalence of sarcopenia in SpA
Presence of periodontal disease and the incidence of inflammatory arthritides
High prevalence of radiographic erosions in PsA
Secukinumab after first-line TNFi for PsA
Mortality in patients with PsA
Sex differences in the effectiveness of first-line TNFi in PsA
Factors associated with diagnostic delay in AS
Please login below to download this issue (PDF)